Overview
Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for the CDC-funded coordinating center of the influenza and other respiratory virus vaccine effectiveness network. This work provides national estimates for influenza and other respiratory virus vaccine effectiveness in persons presenting with respiratory illness in the ambulatory setting.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine effectiveness, vaccine coverage, prevention and treatment of infectious diseases.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.
Journal Article Antimicrob Agents Chemother · June 4, 2025 Fosfomycin, a broad-spectrum antibiotic used for uncomplicated cystitis, represents a potential promising candidate in combating resistant pneumonia. To facilitate the transition of fosfomycin to broader indications, including pneumonia, a minimal physiolo ... Full text Link to item CitePerceived feasibility of a multicomponent prenatal intervention on childhood vaccinations: Findings from a national cross-sectional survey of prenatal care providers, April-June 2022.
Journal Article Int J Gynaecol Obstet · June 2025 BACKGROUND: There are inadequate proactive interventions that take advantage of medical contacts during pregnancy to build confidence in vaccines recommended for children after birth. In addition, prenatal providers' perceptions on implementing such proact ... Full text Link to item CiteFluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.
Journal Article Vaccine · May 22, 2025 The discovery of broadly protective antibodies to the influenza virus neuraminidase (NA) has raised interest in NA as a vaccine target. However, recombinant, solubilized tetrameric NA ectodomains are often challenging to express and isolate, hindering the ... Full text Link to item CiteRecent Grants
Duke University Maternal-Fetal Medicine Units (MFMU) Network Clinical Center
ResearchCollaborating Investigator · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2023 - 2030CISA 2023 Clinical Contributing Task 1
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028CISA 2023 Clinical Contributing Task 2
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028View All Grants